Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary CryptoMapTM platform.
All the latest company news, press releases and updates from Epitopea.
Contact

News & Events:

Revealing the true targets for next generation immunotherapies.
Learn More

Epitopea and Genevant Sciences Announce Collaboration Agreement

Date: December 19, 2024 |
CAMBRIDGE, UK, MONTREAL, CANADA, VANCOUVER, CANADA, and BASEL, SWITZERLAND — December 19, 2024 (GLOBE NEWSWIRE) — Epitopea, a transatlantic cancer […]
Read More

Epitopea Closes USD $31 million Pre-Series A Financing

Date: October 24, 2024 |
Proceeds support strategic development and clinical entry of lead Cryptigen immunotherapeutics CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024 - […]
Read More

CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Platform Enabling the Development of RNA-based Immunotherapies

Date: September 26, 2024 |
Montreal, Quebec, 26 September 2024 – Epitopea, a transatlantic cancer immunotherapy company, and CQDM are proud to announce the launch […]
Read More

Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme

Date: September 12, 2024 |
Grant to advance development of Cryptigen immunotherapeutics for cancer CAMBRIDGE, UK and MONTREAL, CANADA, 12 September 2024 - Epitopea, a […]
Read More

Epitopea Announces Leadership Transition and New Appointments

Date: July 25, 2024 |
Alan C. Rigby Joins as CEO, Jon Moore Transitions to CSO CAMBRIDGE, UK and MONTREAL, CANADA, 25 July 2024 - […]
Read More

Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics

Date: April 25, 2022 |
Novel CryptigenTM technology unlocks full potential of Tumour Specific Antigens CAMBRIDGE, UK and MONTREAL, CANADA, 25 April 2022 - Epitopea, […]
Read More
Revealing Novel Targets For Next Generation Immunotherapies
© 2022 – 2025 Epitopea Ltd | All Rights Reserved
Created by FDM Digital